Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
ETFs with KITE as a Top 10 Holding*
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|0%||BioShares Biotechnology Clinical Trials Fund (BBC)||N/A (N/A)|
Company Description (as filed with the SEC)
We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. We do this using our engineered autologous cell therapy, or eACT, which we believe is a market-redefining approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors, or CARs, or T cell receptors, or TCRs. These modified T cells are designed to recognize and destroy cancer cells. We currently fund a Phase 2 clinical trial of a TCR-based therapy and multiple Phase 1-2a clinical trials of CAR- and TCR-based therapies that are each being conducted by our collaborator, the Surgery Branch of the National Cancer Institute, or the NCI. ... More ...
Where does KITE fit in the risk graph?
|Annual EPS Est:||$-1.64|
|Quarterly EPS Est:||1.16|